Biography: Stefanie Avril, MD
Expertise
Titles
- Associate Professor, CWRU School of Medicine
Education
Residency | Molecular Genetic Pathology
Molecular Genetic Pathology - Technischen Universit?T M?Nchen (2012 - 2013)
Residency | Cytopathology
Cytopathology - Technischen Universit?T M?Nchen (2009 - 2011)
Residency | Anatomic Pathology
Anatomic Pathology - Technischen Universit?T M?Nchen (2008 - 2008)
Research Fellowship | Breast Pathology
Breast Pathology - Cancer Research Uk Cambridge Institute (2006 - 2008)
Residency | Anatomic Pathology
Anatomic Pathology - Technischen Universit?T M?Nchen (2004 - 2006)
Medical Education
Technischen Universit?T M?Nchen (2004)
About
Stefanie Avril (Sassen), MD, is a faculty member of the Department of Pathology, School of Medicine and a Member, of the Hematopoietic and Immune Cancer Biology Program, Case Comprehensive Cancer Center. She started her career in academic pathology in 2004 at the Department of Pathology, Technical University Munich, Germany. Her research is focused on breast cancer and gynecologic oncology, with a specific interest in prediction of treatment response and the tumor immune microenvironment. She has published several studies on prediction of treatment response in ovarian and breast cancer using FDG-PET molecular imaging, as well the histopathological parameters of treatment response and recurrence risk in ovarian cancers and borderline tumors. She has mentored Gynecologic Oncology fellows in translational research and precepts them to enhance their skills in Gynecologic Pathology interpretation.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Stefanie Avril did not disclose any Outside Relationships with Industry.